Treating Contact Lens Discomfort With Cyclosporine 0.1% Ophthalmic Solution

ClinicalTrials.gov ID: NCT07904728

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07904728. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Clinical Evaluation of Treating Contact Lens Discomfort With Water-Free Cyclosporine 0.1% Ophthalmic Solution

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Of the 140 million contact lens (CL) wearers worldwide, most wear soft contact lenses. Despite major improvements in contact lens care, nearly 20% of wearers stop using lenses, with contact lens discomfort (CLD) being the main reason. This study aims to determine whether VEVYE, a water-free 0.1% cyclosporine ophthalmic solution indicated for the treatment of DED, can improve contact lens comfort in people with dry eye disease.

Study identification

NCT ID: NCT07904728
Recruitment status: Recruiting
Study type: Interventional
Phase: Not applicable
Lead sponsor: Ocular Aesthetics, LLC dba Ocular Clinical Trials; Other
Enrollment: 50 participants

Conditions and interventions

Conditions

Interventions

Cyclosporine 0.1% Ophthalmic Solution Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 25, 2026 (Actual)
Primary completion: Mar 15, 2027 (Estimated)
Completion: Apr 15, 2027 (Estimated)
Last update posted: Oct 29, 2026

2026 – 2027

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Ocular Clinical Trials	Houston	Texas	77027	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07904728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 29, 2026 · Synced Nov 14, 2026